MedTrace Logo

A Trial of Enteral Colostrum on Clinical Outcomes in Critically Ill Patients

NCT03019250 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-11-13

No results posted yet for this study

Summary

Enteral administration of immune-modulating nutrients such as glutamine, omega-3 fatty acids, selenium, and antioxidants has been suggested to reduce infections and improve recovery from critical illness. However, the effects of colostrum on clinical outcomes in critical ill patients has not been investigated. In current trial, intensive care unit patients with enteral feeding will receive either enteral colostrum or maltodextrin as placebo.

Conditions

  • Critical Illness
  • Infection Complication
  • Multiple Organ Dysfunction Syndrome

Interventions

DIETARY_SUPPLEMENT

Colostrum

Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.

DIETARY_SUPPLEMENT

Maltodextrin

Maltodextrin mixed with water given via NG tube Q 4 hours.

Sponsors & Collaborators

  • National Nutrition and Food Technology Institute

    lead OTHER

Principal Investigators

  • Ghazaleh Eslamian, MS,PhDcandid · National Nutrition and Food Technology Research Institute Shahid Beheshti University of Medical Sciences, Tehran, Iran

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-15
Primary Completion
2018-11-07
Completion
2018-11-07

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03019250 on ClinicalTrials.gov